Uma Borate, MBBS
Uma Borate, MBBS, is a hematologist specializing in the treatment of myelodysplastic syndromes, acute myeloid leukemia, myeloproliferative neoplasms, and clonal cytopenias of unknown significance. She received he master of science in pathobiology and molecular medicine from the University of Cincinnati and completed a fellowship in hematology/oncology at the University of Alabama.
Articles
MANIFEST-2: Pelabresib plus Ruxolitinib in JAK Inhibitor–Naïve Myelofibrosis
January 17th 2024Uma Borate, MBBS, and the Oncology Brothers provide insights gleaned from the MANIFEST-2 study, a phase 3, randomized, double-blind study on pelabresib plus ruxolitinib for JAK inhibitor treatment–naïve patients with myelofibrosis.
TRANSFORM-1: Navitoclax and Ruxolitinib in Untreated Myelofibrosis
January 17th 2024Following ASH 2023, Uma Borate, MBBS, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from the TRANSFORM-1 trial investigating navitoclax plus ruxolitinib in patients with untreated myelofibrosis.
